Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q0HZ
|
||||
| Former ID |
DIB001576
|
||||
| Drug Name |
Elpamotide
|
||||
| Synonyms |
OTS-102; VEGFR2-169; Epitope peptide vaccine (pancreatic cancer), Wakayama University; VEGFR2-epitope peptide, Wakayama
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Biliary cancer [ICD10:C22, C24] | Phase 1/2 | [522286] | ||
| Company |
OncoTherapy Science Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C47H76N16O13
|
||||
| Canonical SMILES |
N([C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=<br />O)N[C@H](C(=O)N[C@H](C(=O)O)[C@@H](C)CC)CCCNC(=N)N)CC(=<br/>O)N)CC(=O)O)CCC1)C(C)C)C(=O)[C@@H](NC(=O)[C@@H](N)CCCNC<br />(=N)N)Cc1ccccc1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [532029] | ||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.